The Switzerland-based Nestlé Institute of Health Sciences has signed a research collaboration agreement with biopharmaceutical company AC Immune to develop an assay for early Alzheimer’s disease.
The collaboration seeks to develop the minimally invasive Tau diagnostic assay by applying Nestlé’s multiplexed antibody technology platform.
The goal of the collaboration is to identify Alzheimer’s patients at an early and potentially pre-symptomatic stage of the disease, NIHS says.
Tangles of Tau proteins are recognized as a major hallmark of neurodegeneration, as they accumulate inside the brain cells and spread between cells over a long period of time. — Michael Cipriano